Long-Term Partial Remission with Capecitabine/Trastuzumab in a Patient with Metastatic Breast Cancer Following Progression on Trastuzumab Alone |
| |
Authors: | Uleer Christoph Yazdan-Pourfard Jasmin Holland Bernhard Karl-Friedrich Bürrig Moisidis-Tesch Christina von Minckwitz Gunter |
| |
Institution: | Gynecologic Oncology Group Practice Hildesheim, Neu-Isenburg, Germany. |
| |
Abstract: | BACKGROUND: Since the introduction of trastuzumab into the treatment of Her-2/neu-positive metastatic breast cancer, cases of long-term survival have become more frequent. Even after tumor progression, trastuzumab seems to retain its antitumor activity which is potentiated by the combination with a chemotherapeutic agent. CASE REPORT: We are reporting about the unusual clinical course of a young patient with Her-2/neu-positive breast cancer, who experienced progression of pulmonary and bone metastases under treatment with trastuzumab. Upon progression, a combination therapy with capecitabine/trastuzumab was initiated, and a partial remission was achieved which has continued for over 4 years. CONCLUSION: This unusual clinical course shows that continuing trastuzumab-based therapy beyond progression is a safe, effective, and well-tolerated option which can induce long-term remissions in some patients with Her-2/neu-positive metastatic breast cancer. |
| |
Keywords: | Breast cancer Metastasized Capecitabine Trastuzumab |
本文献已被 PubMed 等数据库收录! |
|